New lower cutoff for serum high sensitive C-reactive protein in obese women indicates the risk of metabolic syndrome

References

• Alberti, K.G., Zimmet, P., and Shaw, J., 2006. Metabolic syndrome: a new world‐wide definition. A consensus statement from the international diabetes federation. Diabetic medicine, 23 (5), 469–480.
   PubMed Web of Science ®Google Scholar
• Ärnlöv, J., et al., 2010. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation, 121 (2), 230–236.
   PubMed Web of Science ®Google Scholar
• Babio, N., et al., 2013. White blood cell counts as risk markers of developing metabolic syndrome and its components in the PREDIMED study. PLoS one, 8 (3), e58354.
   PubMed Web of Science ®Google Scholar
• Balta, S., et al., 2013. Higher neutrophil to lymphocyte ratio in patients with metabolic syndrome. Clinical and applied thrombosis/hemostasis, 19 (5), 579.
   PubMed Web of Science ®Google Scholar
• Bonora, E., et al., 2003. Metabolic syndrome: epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study. International journal of obesity, 27 (10), 1283.
   PubMed Web of Science ®Google Scholar
• Czarnywojtek, A., et al., 2014. The role of serum C-reactive protein measured by high-sensitive method in thyroid disease. Archivum immunologiae et therapiae experimentalis, 62 (6), 501–509.
   PubMed Web of Science ®Google Scholar
• Emerging Risk Factors Collaboration, 2012. C-reactive protein, fibrinogen, and cardiovascular disease prediction. New England journal of medicine, 367, 1310–1320.
   PubMed Web of Science ®Google Scholar
• Fadini, G.P., et al., 2012. Elevated white blood cell count is associated with prevalence and development of the metabolic syndrome and its components in the general population. Acta diabetologica, 49 (6), 445–451.
   PubMed Web of Science ®Google Scholar
• Ford, E.S., 2003. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis, 168 (2), 351–358.
   PubMed Web of Science ®Google Scholar
• Galassi, A., Reynolds, K., and He, J., 2006. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. The American journal of medicine, 119 (10), 812–819.
   PubMed Web of Science ®Google Scholar
• Guo, S., 2014. Insulin signaling, resistance, and metabolic syndrome: insights from mouse models into disease mechanisms. Journal of endocrinology, 220 (2), T1–T23.
   PubMed Web of Science ®Google Scholar
• Gutaj, P., et al., 2016. Determinants of C-reactive protein concentrations in pregnant women with type 1 diabetes. Polskie archiwum medycyny wewnetrznej, 126 (4), 230.
   PubMed Web of Science ®Google Scholar
• Han, T.S., et al., 2002. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes care, 25 (11), 2016–2021.
   PubMed Web of Science ®Google Scholar
• Indulekha, K., Surendar, J., and Mohan, V., 2011. High sensitivity C-reactive protein, tumor necrosis factor-α, interleukin-6, and vascular cell adhesion molecule-1 levels in Asian Indians with metabolic syndrome and insulin resistance (CURES-105). Journal of diabetes science and technology, 5 (4), 982–988.
   PubMedGoogle Scholar
• Khan, U.I., et al., 2011. Burden of subclinical cardiovascular disease in “metabolically benign” and “at-risk” overweight and obese women: the Study of Women's Health Across the Nation (SWAN). Atherosclerosis, 217 (1), 179–186.
   PubMed Web of Science ®Google Scholar
• Kovarova, M., et al., 2015. Thyroid-stimulating hormone concentration as an independent risk factor of venous thromboembolism regardless of thyroid function. Endokrynologia polska, 66 (6), 474–479.
   PubMed Web of Science ®Google Scholar
• Krysiak, R., et al., 2015. Comparison of the effects of hypolipidemic treatment on monocyte proinflammatory cytokine release in men and women with type 2 diabetes and atherogenic dyslipidemia. Endokrynologia polska, 66 (3), 224–230.
   PubMedGoogle Scholar
• Kuk, J.L. and Ardern, C.I., 2009. Are metabolically normal but obese individuals at lower risk for all-cause mortality? Diabetes care, 32 (12), 2297–2299.
   PubMed Web of Science ®Google Scholar
• Lakoski, S.G., et al., 2006. Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. American heart journal, 152 (3), 593–598.
   PubMed Web of Science ®Google Scholar
• Liang, Y., et al., 2015. Childhood obesity affects adult metabolic syndrome and diabetes. Endocrine, 50 (1), 87–92.
   PubMed Web of Science ®Google Scholar
• Meigs, J.B., et al., 2007. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes care, 30 (5), 1219–1225.
   PubMed Web of Science ®Google Scholar
• Nakanishi, N., Shiraishi, T., and Wada, M., 2005. C-reactive protein concentration is more strongly related to metabolic syndrome in women than in men—the Minoh study. Circulation journal, 69 (4), 386–391.
   PubMed Web of Science ®Google Scholar
• Oda, E., 2012. Metabolic syndrome: its history, mechanisms, and limitations. Acta diabetologica, 49 (2), 89–95.
   PubMed Web of Science ®Google Scholar
• Oda, E. and Kawai, R., 2010. Comparison between high-sensitivity C-reactive protein (hs-CRP) and white blood cell count (WBC) as an inflammatory component of metabolic syndrome in Japanese. Internal medicine, 49 (2), 117–124.
   PubMed Web of Science ®Google Scholar
• Owecki, M., 2009. Fat tissue and adiponectin: new players in critical care? Critical care (London, England), 13 (4), 174.
   PubMed Web of Science ®Google Scholar
• Owecki, M., et al., 2009. Serum resistin is related to plasma HDL cholesterol and inversely correlated with LDL cholesterol in diabetic and obese humans. Neuro endocrinology letters, 31 (5), 673–678.
   Web of Science ®Google Scholar
• Park, J., et al., 2011. Obesity phenotype and cardiovascular changes. Journal of hypertension, 29 (9), 1765–1772.
   PubMed Web of Science ®Google Scholar
• Pradhan, A.D., et al., 2001. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA, 286 (3), 327–334.
   PubMed Web of Science ®Google Scholar
• Ridker, P.M., 2003. Cardiology patient page. C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation, 108 (12), e81–e85.
   PubMedGoogle Scholar
• Ridker, P.M., et al., 2003. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation, 107 (3), 391–397.
   PubMed Web of Science ®Google Scholar
• Roberson, L.L., et al., 2014. Beyond BMI: the “Metabolically healthy obese” phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality—a systematic review. BMC public health, 14 (1), 1.
   PubMedGoogle Scholar
• Saltevo, J., et al., 2008. Gender differences in C‐reactive protein, interleukin‐1 receptor antagonist and adiponectin levels in the metabolic syndrome: a population‐based study. Diabetic medicine, 25 (6), 747–750.
   PubMed Web of Science ®Google Scholar
• Sattar, N., et al., 2003. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation, 108 (4), 414–419.
   PubMed Web of Science ®Google Scholar
• Simmons, R., et al., 2010. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia, 53 (4), 600–605.
   PubMed Web of Science ®Google Scholar
• Targher, G., et al., 1996. The white blood cell count: its relationship to plasma insulin and other cardiovascular risk factors in healthy male individuals. Journal of internal medicine, 239 (5), 435–441.
   PubMed Web of Science ®Google Scholar
• Tsai, J.C.R., et al., 2007. Association of peripheral total and differential leukocyte counts with metabolic syndrome and risk of ischemic cardiovascular diseases in patients with type 2 diabetes mellitus. Diabetes/metabolism research and reviews, 23 (2), 111–118.
   PubMed Web of Science ®Google Scholar